Rare Journeys
Real Impact
Providing bespoke end-to-end commercialisation solutions for rare disease innovators launching medicines in Europe.
A selection of our trusted partners
A complete end-to-end solution made for the rare disease product lifecycle
Designed for biotech and pharmaceutical firms, our innovative commercialisation solution simplifies the complex issues involved in multi-market drug launches.
Rare diseases focus
We drive treatment access for conventionally underserved patient groups with high unmet needs.
European footprint
We deliver market knowledge and infrastructure to launch products in over 16 European markets.
Tailored solutions
We combine decades of industry experience from big pharma to life science consultancy.
Deep expertise
We scope each program to align with the unique requirements and strategy of our partners.
Novel therapies
Accelerate launch trajectories
A comprehensive suite of services designed specifically to support the end-to-end commercialisation needs of biotech and pharmaceutical companies focused on orphan drug development.
Established brands
Optimise multi-market operations
A selection of services to enable secure access to local markets in a time and resource-efficient manner, including multi-market tender and supply chain management.
Ready to take the next step?
Let us share how we could successfully support your product commercialisation.
Therapeutic areas
Genetic & Metabolic Disorders
Haematology & Oncology
CNS & Neurology
Latest insights
Stay abreast of key issues and critical thinking within the European rare disease community.
